Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11 years.

Maria Christina L OliveiraMaria Christina L OliveiraAna Cristina Simões E SilvaEnrico A ColosimoRobert H MakMariana A VasconcelosLudmila R SilvaDaniella B MartelliClara C PinhatiHercílio Martelli-Júnior

Published in: World journal of pediatrics : WJP (2023)

For hospitalized children aged 5-11 years during the omicron-predominant period in Brazil, two doses of both vaccines had moderate effectiveness against hospitalization with acute respiratory symptoms and SARS-CoV-2 infection and offered limited protection against endpoints of COVID-19 severity.

Keyphrases

randomized controlled trial
systematic review
coronavirus disease
sars cov
liver failure
respiratory syndrome coronavirus
young adults
respiratory failure
high intensity
sleep quality
physical activity
depressive symptoms
respiratory tract